File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.

TitleAssociation between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.
Authors
KeywordsAdvanced glycation end products
Nephropathy
Soluble receptor for advanced glycation end product
Type 2 diabetes mellitus
Issue Date2006
PublisherSpringer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/00125/index.htm
Citation
Diabetologia, 2006, v. 49 n. 11, p. 2756-2762 How to Cite?
AbstractAIMS/HYPOTHESIS: Activation of the receptor for advanced glycation end products (RAGE, also known as AGE-specific receptor [AGER]) has been implicated in the development of diabetic vascular complications. Blockade of RAGE using a soluble form of the receptor (sRAGE) suppressed vascular hyperpermeability and atherosclerosis in animal models. Since little is known about the regulation of endogenous sRAGE levels, we determined whether serum sRAGE is influenced by circulating AGEs and the severity of nephropathy in type 2 diabetic patients. MATERIALS AND METHODS: We recruited 150 healthy control and 318 diabetic subjects. Diabetic subjects were subdivided into those with proteinuria, microalbuminuria or normoalbuminuria. Serum sRAGE was assayed by ELISA and serum AGEs by competitive ELISA using a polyclonal rabbit antiserum raised against AGE-RNase. RESULTS: Diabetic subjects had higher sRAGE (1,029.5 pg/ml [766.1-1,423.0] interquartile range vs 1,002.6 [726.5-1,345.3], p<0.05) and AGEs (4.07+/-1.13, SD, unit/ml vs 3.39+/-1.05, p<0.01) than controls. Proteinuric subjects had the highest sRAGE levels and there was a significant trend between the severity of nephropathy and sRAGE (p=0.01). In diabetic subjects, serum log(sRAGE) correlated with AGEs (r=0.27, p<0.001), log(plasma creatinine) (r=0.31, p<0.001), log(urine AER) (r=0.24, p<0.01) and log(triglycerides) (r=0.15, p<0.01). On stepwise linear regression analysis, AGEs and creatinine levels were the main independent determinants of sRAGE concentration. CONCLUSIONS/INTERPRETATION: Serum sRAGE levels and circulating AGEs are associated with the severity of nephropathy in type 2 diabetic patients. Prospective studies are required to determine whether endogenous sRAGE potentially influences the development of diabetic vascular complications.
Persistent Identifierhttp://hdl.handle.net/10722/77361
ISSN
2015 Impact Factor: 6.206
2015 SCImago Journal Rankings: 3.528
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorTan, KCen_HK
dc.contributor.authorShiu, SWen_HK
dc.contributor.authorChow, WSen_HK
dc.contributor.authorLeng, Len_HK
dc.contributor.authorBucala, Ren_HK
dc.contributor.authorBetteridge, DJen_HK
dc.date.accessioned2010-09-06T07:31:04Z-
dc.date.available2010-09-06T07:31:04Z-
dc.date.issued2006en_HK
dc.identifier.citationDiabetologia, 2006, v. 49 n. 11, p. 2756-2762en_HK
dc.identifier.issn0012-186Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/77361-
dc.description.abstractAIMS/HYPOTHESIS: Activation of the receptor for advanced glycation end products (RAGE, also known as AGE-specific receptor [AGER]) has been implicated in the development of diabetic vascular complications. Blockade of RAGE using a soluble form of the receptor (sRAGE) suppressed vascular hyperpermeability and atherosclerosis in animal models. Since little is known about the regulation of endogenous sRAGE levels, we determined whether serum sRAGE is influenced by circulating AGEs and the severity of nephropathy in type 2 diabetic patients. MATERIALS AND METHODS: We recruited 150 healthy control and 318 diabetic subjects. Diabetic subjects were subdivided into those with proteinuria, microalbuminuria or normoalbuminuria. Serum sRAGE was assayed by ELISA and serum AGEs by competitive ELISA using a polyclonal rabbit antiserum raised against AGE-RNase. RESULTS: Diabetic subjects had higher sRAGE (1,029.5 pg/ml [766.1-1,423.0] interquartile range vs 1,002.6 [726.5-1,345.3], p<0.05) and AGEs (4.07+/-1.13, SD, unit/ml vs 3.39+/-1.05, p<0.01) than controls. Proteinuric subjects had the highest sRAGE levels and there was a significant trend between the severity of nephropathy and sRAGE (p=0.01). In diabetic subjects, serum log(sRAGE) correlated with AGEs (r=0.27, p<0.001), log(plasma creatinine) (r=0.31, p<0.001), log(urine AER) (r=0.24, p<0.01) and log(triglycerides) (r=0.15, p<0.01). On stepwise linear regression analysis, AGEs and creatinine levels were the main independent determinants of sRAGE concentration. CONCLUSIONS/INTERPRETATION: Serum sRAGE levels and circulating AGEs are associated with the severity of nephropathy in type 2 diabetic patients. Prospective studies are required to determine whether endogenous sRAGE potentially influences the development of diabetic vascular complications.en_HK
dc.languageengen_HK
dc.publisherSpringer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/00125/index.htmen_HK
dc.relation.ispartofDiabetologiaen_HK
dc.subjectAdvanced glycation end products-
dc.subjectNephropathy-
dc.subjectSoluble receptor for advanced glycation end product-
dc.subjectType 2 diabetes mellitus-
dc.subject.meshBlood Glucose - analysisen_HK
dc.subject.meshBody Mass Indexen_HK
dc.subject.meshDiabetes Mellitus, Type 2 - blooden_HK
dc.subject.meshDiabetic Nephropathies - blood - physiopathologyen_HK
dc.subject.meshEnzyme-Linked Immunosorbent Assayen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshGlycosylation End Products, Advanced - blooden_HK
dc.subject.meshHemoglobin A, Glycosylated - analysisen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLipids - blooden_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshReceptors, Immunologic - blooden_HK
dc.subject.meshReference Valuesen_HK
dc.titleAssociation between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.en_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0012-186X&volume=49&spage=2756&epage=62&date=2006&atitle=Association+between+serum+levels+of+soluble+receptor+for+advanced+glycation+end+products+and+circulating+advanced+glycation+end+products+in+type+2+diabetesen_HK
dc.identifier.emailTan, KC:kcbtan@hku.hken_HK
dc.identifier.authorityTan, KC=rp00402en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s00125-006-0394-1en_HK
dc.identifier.pmid16969649-
dc.identifier.scopuseid_2-s2.0-33947408459en_HK
dc.identifier.hkuros130061en_HK
dc.identifier.volume49en_HK
dc.identifier.issue11en_HK
dc.identifier.spage2756en_HK
dc.identifier.epage2762en_HK
dc.identifier.eissn1432-0428-
dc.identifier.isiWOS:000241578600032-
dc.publisher.placeGermanyen_HK
dc.identifier.scopusauthoridTan, KC=8082703100en_HK
dc.identifier.scopusauthoridShiu, SW=7005550652en_HK
dc.identifier.scopusauthoridChow, WS=7402281153en_HK
dc.identifier.scopusauthoridLeng, L=7006089148en_HK
dc.identifier.scopusauthoridBucala, R=7102379822en_HK
dc.identifier.scopusauthoridBetteridge, DJ=34973752700en_HK
dc.identifier.citeulike1015195-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats